Clinical Trials
18 trialsNCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT02073994 2026-02-17
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
Phase 1 Completed
NCT06387485 2026-02-06
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Ricoh USA, Inc.
Phase NA Recruiting
NCT06645808 2025-12-29
VARTUTRACE
Var2 Pharmaceuticals
Phase EARLY_PHASE1 Recruiting
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT03474640 2024-11-22
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Completed
NCT04673942 2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2 Recruiting
NCT05448820 2023-09-21
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Unknown
NCT01330966 2023-03-10
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Emerald Clinical Inc.
Phase 2 Completed
NCT00543712 2022-12-13
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Genentech, Inc.
Phase 2 Terminated
NCT02273739 2021-02-23
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Phase 1/2 Completed
NCT00401388 2018-03-07
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
AEterna Zentaris
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00948961 2016-06-27
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Phase 1/2 Completed
NCT00413075 2015-07-08
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Phase 1 Completed
NCT00413322 2015-07-08
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT01609179 2012-11-14
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
Infinity Pharmaceuticals, Inc.
Phase NA Completed